Screening and Prevention of Endometrial Cancer and Ovarian Cancer in Patients with Lynch Syndrome

doi:10.12280/gjfckx.20201174

Abstract

Abstract:

Women with Lynch syndrome have a life-long risk of endometrial cancer and ovarian cancer. Endometrial cancer or ovarian cancer can be the first malignant tumor or the second primary malignant tumor in patients with Lynch syndrome. The main type of endometrial cancer associated with Lynch syndrome is endometrioid adenocarcinoma. In recent years, there have been few screening studies on endometrial cancer and ovarian cancer related to Lynch syndrome, mainly through outpatient endometrial biopsy, microsatellite high instability (MSI-H) status or MMR protein mutation and genetic testing to identify precancerous lesions and early cancers. In terms of prevention, oral contraceptives and preventive surgery removing the uterus and ovaries are used. Women with Lynch syndrome have a 40%~60% lifetime risk of endometrial cancer, and a 4%~24% lifetime risk of ovarian cancer. Therefore, it is of great significance for women with Lynch syndrome to have early screening and prevention of endometrial cancer and ovarian cancer.

Key words: Colorectal neoplasms,hereditary nonpolyposis, Endometrial neoplasms, Ovarian neoplasms, Microsatellite instability, Contraceptives,oral, Gynecologic surgical procedures

YANG Zi-hui, LIU Xin-yu, YANG Xi, WEN Jia, ZHANG Qiong-qiong, LIAO Qin-ping. Screening and Prevention of Endometrial Cancer and Ovarian Cancer in Patients with Lynch Syndrome[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 453-456.

References 31

[1]	Sinicrope FA. Lynch Syndrome-Associated Colorectal Cancer[J]. N Engl J Med, 2018, 379(8):764-773. doi: 10.1056/NEJMcp1714533. doi: 10.1056/NEJMcp1714533
[2]	Ryan N, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies[J]. JAMA Oncol, 2017, 3(12):1702-1706. doi: 10.1001/jamaoncol.2017.0619. doi: 10.1001/jamaoncol.2017.0619
[3]	Carr C, Son J, Yao M, et al. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol, 2020, 159(3):712-720. doi: 10.1016/j.ygyno.2020.09.039. doi: 10.1016/j.ygyno.2020.09.039
[4]	Ramchander NC, Ryan N, Walker T, et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol, 2019, 10:3023. doi: 10.3389/fimmu.2019.03023. doi: 10.3389/fimmu.2019.03023 pmid: 31998307
[5]	Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes[J]. Int J Gynecol Cancer, 2020, 30(1):56-61. doi: 10.1136/ijgc-2019-000824. doi: 10.1136/ijgc-2019-000824
[6]	Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome[J]. JAMA, 2011, 305(22):2304-2310. doi: 10.1001/jama.2011.743. doi: 10.1001/jama.2011.743 pmid: 21642682
[7]	Hinchcliff EM, Bednar EM, Lu KH, et al. Disparities in gynecologic cancer genetics evaluation[J]. Gynecol Oncol, 2019, 153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. doi: S0090-8258(19)30066-6 pmid: 30711300
[8]	Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome[J]. J Clin Oncol, 2012, 30(35):4409-4415. doi: 10.1200/JCO.2012.43.2278. doi: 10.1200/JCO.2012.43.2278
[9]	Ryan N, Evans DG, Green K, et al. Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer[J]. Gynecol Oncol, 2017, 144(3):491-495. doi: 10.1016/j.ygyno.2017.01.005. doi: S0090-8258(17)30042-2 pmid: 28065618
[10]	Woolderink JM, De Bock GH, de Hullu JA, et al. Characteristics of Lynch syndrome associated ovarian cancer[J]. Gynecol Oncol, 2018, 150(2):324-330. doi: 10.1016/j.ygyno.2018.03.060. doi: S0090-8258(18)30240-3 pmid: 29880284
[11]	Wadee R, Grayson W. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome[J]. Ann Diagn Pathol, 2019, 39:92-104. doi: 10.1016/j.anndiagpath.2019.02.003. doi: 10.1016/j.anndiagpath.2019.02.003
[12]	Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study[J]. Int J Gynecol Cancer, 2017, 27(5):953-960. doi: 10.1097/IGC.0000000000000985. doi: 10.1097/IGC.0000000000000985 pmid: 28525912
[13]	Conlon N, Da Cruz Paula A, Ashley CW, et al. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations[J]. Am J Surg Pathol, 2020, 44(5):641-648. doi: 10.1097/PAS.0000000000001461. doi: 10.1097/PAS.0000000000001461 pmid: 32205482
[14]	Watson P, Bützow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer[J]. Gynecol Oncol, 2001, 82(2):223-228. doi: 10.1006/gyno.2001.6279. doi: 10.1006/gyno.2001.6279 pmid: 11531271
[15]	Randall ME, Filiaci V, McMeekin DS, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer[J]. J Clin Oncol, 2019, 37(21):1810-1818. doi: 10.1200/JCO.18.01575. doi: 10.1200/JCO.18.01575 pmid: 30995174
[16]	刘芳. 经阴道彩色多普勒超声对子宫内膜息肉及子宫内膜癌的诊断价值分析[J]. 中国医疗器械信息, 2020, 26(24):17-18. doi: 10.15971/j.cnki.cmdi.2020.24.007. doi: 10.15971/j.cnki.cmdi.2020.24.007
[17]	Renkonen-Sinisalo L, Bützow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome[J]. Int J Cancer, 2007, 120(4):821-824. doi: 10.1002/ijc.22446. doi: 10.1002/ijc.22446 pmid: 17096354
[18]	Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members[J]. J Clin Oncol, 2009, 27(28):4793-4797. doi: 10.1200/JCO.2009.23.7784. doi: 10.1200/JCO.2009.23.7784 pmid: 19720893
[19]	Manchanda R, Saridogan E, Abdelraheim A, et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)[J]. Arch Gynecol Obstet, 2012, 286(6):1555-1562. doi: 10.1007/s00404-012-2492-2. doi: 10.1007/s00404-012-2492-2 pmid: 22865035
[20]	Chao X, Li L, Wu M, et al. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China[J]. Cancer Commun(Lond), 2019, 39(1):42. doi: 10.1186/s40880-019-0388-2. doi: 10.1186/s40880-019-0388-2
[21]	杨凤泊, 赵丽君, 徐游贵, 等. 子宫内膜癌组织错配修复基因MMR表达及其临床意义[J]. 现代妇产科进展, 2020, 29(2):120-124,129. doi: 10.13283/j.cnki.xdfckjz.2020.02.009. doi: 10.13283/j.cnki.xdfckjz.2020.02.009
[22]	Benusiglio PR, Coulet F, Lefebvre A, et al. Overcoming the challenges associated with universal screening for Lynch syndrome in colorectal and endometrial cancer[J]. Genet Med, 2020, 22(8):1422-1423. doi: 10.1038/s41436-020-0819-0. doi: 10.1038/s41436-020-0819-0 pmid: 32409733
[23]	Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16(2):170-199. doi: 10.6004/jnccn.2018.0006. doi: 10.6004/jnccn.2018.0006
[24]	Takeda T, Tsuji K, Banno K, et al. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer[J]. J Gynecol Oncol, 2018, 29(3):e29. doi: 10.3802/jgo.2018.29.e29. doi: 10.3802/jgo.2018.29.e29
[25]	Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database[J]. Gut, 2018, 67(7):1306-1316. doi: 10.1136/gutjnl-2017-314057. doi: 10.1136/gutjnl-2017-314057 pmid: 28754778
[26]	Nikolaidis C, Ming C, Pedrazzani C, et al. Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop[J]. Public Health Genomics, 2018, 21(3/4):121-132. doi: 10.1159/000496495. doi: 10.1159/000496495
[27]	Wang Y, Nisenblat V, Tao L, et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience[J]. J Gynecol Oncol, 2019, 30(3):e49. doi: 10.3802/jgo.2019.30.e49. doi: 10.3802/jgo.2019.30.e49
[28]	Crosbie EJ, Ryan N, Arends MJ, et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med, 2019, 21(10):2390-2400. doi: 10.1038/s41436-019-0489-y. doi: 10.1038/s41436-019-0489-y pmid: 30918358
[29]	刘晓荻. 避孕药可以预防卵巢癌[J]. 基础医学与临床, 2019, 39(11):1529.
[30]	McGarragle KM, Aronson M, Semotiuk K, et al. Patient-physician relationships, health self-efficacy, and gynecologic cancer screening among women with Lynch syndrome[J]. Hered Cancer Clin Pract, 2019, 17:24. doi: 10.1186/s13053-019-0123-7. doi: 10.1186/s13053-019-0123-7
[31]	Etchegary H, Dicks E, Tamutis L, et al. Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers[J]. Fam Cancer, 2018, 17(1):53-61. doi: 10.1007/s10689-017-9997-6. doi: 10.1007/s10689-017-9997-6 pmid: 28551770